{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:20:30Z","timestamp":1791350430845,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["grant number RF-2013-02357497"],"award-info":[{"award-number":["grant number RF-2013-02357497"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","award":["grant number 2020\/S\/5"],"award-info":[{"award-number":["grant number 2020\/S\/5"]}],"id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s00415-024-12701-w","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T19:02:09Z","timestamp":1727118129000},"page":"7494-7501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12\u00a0months outcome: data from a real-life clinical setting"],"prefix":"10.1007","volume":"271","author":[{"given":"Simona","family":"Malucchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia Irene","family":"Bava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Valentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Martire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Lo Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bertolotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Di Sapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"12701_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","volume":"22","author":"T Kuhlmann","year":"2023","unstructured":"Kuhlmann T, Moccia M, Coetzee T et al (2023) Multiple sclerosis progression: time for a new mechanism-driven framework. Lancet Neurol 22:78\u201388. https:\/\/doi.org\/10.1016\/S1474-4422(22)00289-7","journal-title":"Lancet Neurol"},{"issue":"9","key":"12701_CR2","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1093\/brain\/awaa145","volume":"143","author":"PS Sorensen","year":"2020","unstructured":"Sorensen PS, Sellebjerg F, Hartung HP et al (2020) The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. Brain 143(9):2637\u20132652. https:\/\/doi.org\/10.1093\/brain\/awaa145","journal-title":"Brain"},{"issue":"1","key":"12701_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00415-023-11969-8","volume":"271","author":"K Selmaj","year":"2024","unstructured":"Selmaj K, Cree BAC, Barnett M et al (2024) Multiple sclerosis: time for early treatment with high-efficacy drugs. J Neurol 271(1):105\u2013115. https:\/\/doi.org\/10.1007\/s00415-023-11969-8","journal-title":"J Neurol"},{"issue":"3","key":"12701_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","volume":"8","author":"E Havrdova","year":"2009","unstructured":"Havrdova E, Galetta S, Hutchinson M et al (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 8(3):254\u2013260. https:\/\/doi.org\/10.1016\/S1474-4422(09)70021-3","journal-title":"Lancet Neurol"},{"issue":"2","key":"12701_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","volume":"72","author":"DL Rotstein","year":"2015","unstructured":"Rotstein DL, Healy BC, Malik MT et al (2015) Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. JAMA Neurol 72(2):152\u2013158. https:\/\/doi.org\/10.1001\/jamaneurol.2014.3537","journal-title":"JAMA Neurol"},{"issue":"3","key":"12701_CR6","doi-asserted-by":"publisher","first-page":"205521731878335","DOI":"10.1177\/2055217318783352","volume":"4","author":"H Gyllensten","year":"2018","unstructured":"Gyllensten H, Kavaliunas A, Alexanderson K et al (2018) Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden. Mult Scler J Exp Transl Clin 4(3):2055217318783352. https:\/\/doi.org\/10.1177\/2055217318783352","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"12701_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1212\/WNL.0000000000008319","volume":"93","author":"C Tur","year":"2019","unstructured":"Tur C, Kalincik T, Oh J et al (2019) Head-to-head drug comparisons in multiple sclerosis: urgent action needed. Neurol 93:793\u2013809. https:\/\/doi.org\/10.1212\/WNL.0000000000008319","journal-title":"Neurol"},{"issue":"13","key":"12701_CR8","doi-asserted-by":"publisher","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","volume":"95","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Kappos L, Arnold DL et al (2020) Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurol 95(13):e1854\u2013e1867. https:\/\/doi.org\/10.1212\/WNL.0000000000010376","journal-title":"Neurol"},{"key":"12701_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104031","volume":"66","author":"IA Samjoo","year":"2022","unstructured":"Samjoo IA, Klotz L, Giovannoni G et al (2022) Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I\/II versus ocrelizumab in OPERA I\/II for the treatment of patients with relapsing multiple sclerosis. Mult Scler Relat Disord 66:104031. https:\/\/doi.org\/10.1016\/j.msard.2022.104031. (Epub 2022 Jul 4)","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"12701_CR10","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac01","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H et al (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147\u201331616. https:\/\/doi.org\/10.1093\/brain\/awac01","journal-title":"Brain"},{"issue":"4","key":"12701_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.it.2023.02.002","volume":"44","author":"RM Ransohoff","year":"2023","unstructured":"Ransohoff RM (2023) Multiple sclerosis: role of meningeal lymphoid aggregates in progression independent of relapse activity. Trends Immunol 44(4):266\u2013275. https:\/\/doi.org\/10.1016\/j.it.2023.02.002","journal-title":"Trends Immunol"},{"issue":"8","key":"12701_CR12","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41582-023-00838-7","volume":"19","author":"R Magliozzi","year":"2023","unstructured":"Magliozzi R, Howell OW, Calabrese M, Reynolds R (2023) Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis. Nat Rev Neurol 19(8):461\u2013476. https:\/\/doi.org\/10.1038\/s41582-023-00838-7","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"12701_CR13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001139","volume":"9","author":"P Preziosa","year":"2022","unstructured":"Preziosa P, Pagani E, Meani A et al (2022) Slowly expanding lesions predict 9-year multiple sclerosis disease progression. Neurol Neuroimmunol Neuroinflamm 9(2):e1139. https:\/\/doi.org\/10.1212\/NXI.0000000000001139","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"12701_CR14","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/s41582-022-00654-5","volume":"18","author":"H Wood","year":"2022","unstructured":"Wood H (2022) Slowly expanding lesions are linked to multiple sclerosis progression. Nat Rev Neurol 18(5):252. https:\/\/doi.org\/10.1038\/s41582-022-00654-5","journal-title":"Nat Rev Neurol"},{"key":"12701_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2022.103048","volume":"35","author":"A Calvi","year":"2022","unstructured":"Calvi A, Tur C, Chard D, Stutters J et al (2022) Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. Neuroimage Clin 35:103048. https:\/\/doi.org\/10.1016\/j.nicl.2022.103048","journal-title":"Neuroimage Clin"},{"key":"12701_CR16","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26913","author":"M Calabrese","year":"2024","unstructured":"Calabrese M, Preziosa P, Scalfari A et al (2024) Determinants and biomarkers of progression independent of relapses in multiple sclerosis. Ann Neurol. https:\/\/doi.org\/10.1002\/ana.26913","journal-title":"Ann Neurol"},{"key":"12701_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-023-00549-7","author":"SD Newsome","year":"2023","unstructured":"Newsome SD, Binns C, Kaunzner UW et al (2023) No evidence of disease activity (NEDA) as a clinical assessment tool for multiple sclerosis: clinician and patient perspectives [Narrative Review]. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-023-00549-7","journal-title":"Neurol Ther"},{"issue":"6","key":"12701_CR18","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1212\/WNL.0000000000012326","volume":"97","author":"P Maggi","year":"2021","unstructured":"Maggi P, Kuhle J, Schadelin S et al (2021) Chronic white matter inflammation and serum neurofilament levels in multiple sclerosis. Neurol 97(6):e543\u2013e553. https:\/\/doi.org\/10.1212\/WNL.0000000000012326","journal-title":"Neurol"},{"issue":"9","key":"12701_CR19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1136\/jnnp-2023-331051","volume":"94","author":"M Saraste","year":"2023","unstructured":"Saraste M, Matilainen M, Vuorimaa A et al (2023) Association of serum neurofilament light with microglial activation in multiple sclerosis. J Neurol Neurosurg Psichiatry 94(9):698\u2013706. https:\/\/doi.org\/10.1136\/jnnp-2023-331051","journal-title":"J Neurol Neurosurg Psichiatry"},{"issue":"10","key":"12701_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"12701_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ana.24954","volume":"81","author":"G Disanto","year":"2017","unstructured":"Disanto G, Barro C, Benkert P et al (2017) Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81(6):857\u2013870. https:\/\/doi.org\/10.1002\/ana.24954","journal-title":"Ann Neurol"},{"issue":"8","key":"12701_CR22","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1093\/brain\/awy154","volume":"141","author":"C Barro","year":"2018","unstructured":"Barro C, Benkert P, Disanto G et al (2018) Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain 141(8):2382\u20132391. https:\/\/doi.org\/10.1093\/brain\/awy154","journal-title":"Brain"},{"issue":"12","key":"12701_CR23","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/acn3.638","volume":"5","author":"T Chitnis","year":"2018","unstructured":"Chitnis T, Gonzalez C, Healy BC et al (2018) Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann Clin Transl Neurol 5(12):1478\u20131491. https:\/\/doi.org\/10.1002\/acn3.638","journal-title":"Ann Clin Transl Neurol"},{"issue":"10","key":"12701_CR24","doi-asserted-by":"publisher","first-page":"e1007","DOI":"10.1212\/WNL.0000000000007032","volume":"92","author":"J Kuhle","year":"2019","unstructured":"Kuhle J, Kropshofer H, Haering DA et al (2019) Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurol 92(10):e1007\u2013e1015. https:\/\/doi.org\/10.1212\/WNL.0000000000007032","journal-title":"Neurol"},{"issue":"5","key":"12701_CR25","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000599","volume":"6","author":"D Leppert","year":"2019","unstructured":"Leppert D, Kuhle J (2019) Blood neurofilament light chain at the doorstep of clinical application. Neurol Neuroimmunol NeuroInflamm 6(5):e599. https:\/\/doi.org\/10.1212\/NXI.0000000000000599","journal-title":"Neurol Neuroimmunol NeuroInflamm"},{"key":"12701_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102807","volume":"56","author":"S Bittner","year":"2020","unstructured":"Bittner S, Steffen F, Uphaus T et al (2020) Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study. EBioMedicine 56:102807. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102807","journal-title":"EBioMedicine"},{"key":"12701_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103090","volume":"54","author":"P Valentino","year":"2021","unstructured":"Valentino P, Marnetto F, Martire S et al (2021) Serum neurofilament light chain levels in healthy individuals: a proposal cut-off values for use in multiple sclerosis clinical practice. Mult Scler Relat Disord 54:103090. https:\/\/doi.org\/10.1016\/j.msard.2021.103090","journal-title":"Mult Scler Relat Disord"},{"key":"12701_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104176","volume":"67","author":"P Valentino","year":"2022","unstructured":"Valentino P, Malucchi S, Martire S et al (2022) sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients. Mult Scler Relat Disord 67:104176. https:\/\/doi.org\/10.1016\/j.msard.2022.104176","journal-title":"Mult Scler Relat Disord"},{"key":"12701_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104893","volume":"77","author":"P Valentino","year":"2023","unstructured":"Valentino P, Malucchi S, Bava CI et al (2023) Serum neurofilament are a reliable biomarker to early detect PML in Multiple Sclerosis patients. Mult Scler Relat Disord 77:104893. https:\/\/doi.org\/10.1016\/j.msard.2023.104893","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"12701_CR30","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"12701_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","volume":"4","author":"G Giovannoni","year":"2015","unstructured":"Giovannoni G, Turner B, Gnanapavan S et al (2015) Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Mult Scler Relat Disord 4:329\u2013333. https:\/\/doi.org\/10.1016\/j.msard.2015.04.006","journal-title":"Mult Scler Relat Disord"},{"key":"12701_CR32","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.msard.2017.07.011","volume":"20","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G, Bermel R, Phillips T et al (2018) A brief history of NEDA. Mult Scler Relat Disord 20:228\u2013230. https:\/\/doi.org\/10.1016\/j.msard.2017.07.011","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"12701_CR33","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR et al (2017) \u2018\u201cNo evident disease activity\u201d\u2019: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler 23(9):1179\u20131187. https:\/\/doi.org\/10.1177\/1352458517703193","journal-title":"Mult Scler"},{"key":"12701_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1177\/1352458520974938","volume":"26","author":"F Marnetto","year":"2020","unstructured":"Marnetto F, Valentino P, Caldano M et al (2020) BBcresm: a structured institutional biobank for quality research in multiple sclerosis-LB1245. Mult Scler J 26:43\u2013117. https:\/\/doi.org\/10.1177\/1352458520974938","journal-title":"Mult Scler J"},{"key":"12701_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1177\/1352458509356368","volume":"16","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Tumani HT, Bennett JL et al (2009) Short commentary on a \u201cconsensus protocol for the standardization of cerebrospinal fluid collection and biobanking.\u201d Mult Scler 16:129\u2013132. https:\/\/doi.org\/10.1177\/1352458509356368","journal-title":"Mult Scler"},{"key":"12701_CR36","doi-asserted-by":"publisher","first-page":"P706","DOI":"10.1016\/j.jalz.2018.06.783","volume":"14","author":"J Lambert","year":"2018","unstructured":"Lambert J, Chang L, Song L et al (2018) Comparison of two platforms quantitating Fg\/Ml neurological biomarkers using single molecule arrays and digital elisa: the benchtop reader Sr-X TM and the Fully Automated Analyzer Hd-1 TM. Alzheimer\u2019s Dement. 14:P706\u2013P706. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.783","journal-title":"Alzheimer\u2019s Dement."},{"key":"12701_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-022-11193-w","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D et al (2022) Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. https:\/\/doi.org\/10.1007\/s00415-022-11193-w","journal-title":"J Neurol"},{"key":"12701_CR38","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaneurol.2023.3997","volume":"80","author":"A Abdelhak","year":"2023","unstructured":"Abdelhak A, Benkert P, Schaedelin S et al (2023) Neurofilament light chain elevation and disability progression in multiple sclerosis. JAMA Neurol 80:1317","journal-title":"JAMA Neurol"},{"issue":"3","key":"12701_CR39","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P, Meier S, Schaedelin S et al (2022) Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol 21(3):246\u2013257","journal-title":"Lancet Neurol"},{"key":"12701_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.104970","volume":"101","author":"MS Freedman","year":"2024","unstructured":"Freedman MS, Gnanapavan S, Booth RA, Calabresi PA et al (2024) Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine 101:104970. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104970","journal-title":"EBioMedicine"},{"issue":"1","key":"12701_CR41","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","volume":"77","author":"K Bjornevik","year":"2020","unstructured":"Bjornevik K, Munger KL, Cortese M et al (2020) Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. Jama Neurol 77(1):58\u201364. https:\/\/doi.org\/10.1001\/jamaneurol.2019.3238","journal-title":"Jama Neurol"}],"updated-by":[{"DOI":"10.1007\/s00415-025-13107-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000}}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12701-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12701-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12701-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T09:02:36Z","timestamp":1749114156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12701-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["12701"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12701-w","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00415-025-13107-y","asserted-by":"object"}]},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00415-025-13107-y","URL":"https:\/\/doi.org\/10.1007\/s00415-025-13107-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Malucchi Simona received compensation for speaking and consulting from Biogen, Merck, Novartis, Roche. Valentino Paola received speaker honoraria from Roche, research support from Merck, grant support from Quanterix. Bava Cecilia Irene: nothing to discose. Martire Serena: nothing to disclose. Di Sapio Alessia received compensation for speaking and consulting by Biogen, Novartis, Roche, Sanofi, Alexion, Sandoz and reimbursement by Merck, Biogen, Genzyme and Roche for attending conferences. Lo Re Marianna received compensation for consulting by Novartis. Bertolotto Antonio served on the scientific advisory board of Almirall, Bayer, Biogen, Genzyme; received speaker honoraria from Biogen, Novartis, Sanofi, grant support from Almiral, Biogen, Associazione San Luigi Gonzaga ONLUS, Fondazione per la Ricerca Biomedica ONLUS, Mylan, Novartis and the Italian Multiple sclerosis Society.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the ethical committee of San Luigi Gonzaga University Hospital (approvals number 7262\/2019 and 18,390\/2019). All participants provided informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}